150 related articles for article (PubMed ID: 16946998)
1. A semi-physiological population pharmacokinetic model describing the non-linear disposition of indisulam.
Zandvliet AS; Schellens JH; Copalu W; Beijnen JH; Huitema AD
J Pharmacokinet Pharmacodyn; 2006 Oct; 33(5):543-70. PubMed ID: 16946998
[TBL] [Abstract][Full Text] [Related]
2. Saturable binding of indisulam to plasma proteins and distribution to human erythrocytes.
Zandvliet AS; Copalu W; Schellens JH; Beijnen JH; Huitema AD
Drug Metab Dispos; 2006 Jun; 34(6):1041-6. PubMed ID: 16565173
[TBL] [Abstract][Full Text] [Related]
3. Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam.
van Kesteren C; Zandvliet AS; Karlsson MO; Mathôt RA; Punt CJ; Armand JP; Raymond E; Huitema AD; Dittrich C; Dumez H; Roché HH; Droz JP; Ravic M; Yule SM; Wanders J; Beijnen JH; Fumoleau P; Schellens JH
Invest New Drugs; 2005 Jun; 23(3):225-34. PubMed ID: 15868378
[TBL] [Abstract][Full Text] [Related]
4. PK/PD model of indisulam and capecitabine: interaction causes excessive myelosuppression.
Zandvliet AS; Siegel-Lakhai WS; Beijnen JH; Copalu W; Etienne-Grimaldi MC; Milano G; Schellens JH; Huitema AD
Clin Pharmacol Ther; 2008 Jun; 83(6):829-39. PubMed ID: 17851564
[TBL] [Abstract][Full Text] [Related]
5. A randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancer.
Talbot DC; von Pawel J; Cattell E; Yule SM; Johnston C; Zandvliet AS; Huitema AD; Norbury CJ; Ellis P; Bosquee L; Reck M
Clin Cancer Res; 2007 Mar; 13(6):1816-22. PubMed ID: 17363538
[TBL] [Abstract][Full Text] [Related]
6. In vitro pharmacokinetic study of the novel anticancer agent E7070: red blood cell and plasma protein binding in human blood.
Bongard HJ; Pluim D; Waardenburg RC; Ravic M; Beijnen JH; Schellens JH
Anticancer Drugs; 2003 Jul; 14(6):405-10. PubMed ID: 12853880
[TBL] [Abstract][Full Text] [Related]
7. Covariate-based dose individualization of the cytotoxic drug indisulam to reduce the risk of severe myelosuppression.
Zandvliet AS; Schellens JH; Copalu W; Beijnen JH; Huitema AD
J Pharmacokinet Pharmacodyn; 2009 Feb; 36(1):39-62. PubMed ID: 19199010
[TBL] [Abstract][Full Text] [Related]
8. Dose-dependent pharmacokinetics of L-693,612, a carbonic anhydrase inhibitor, following oral administration in rats.
Wong BK; Bruhin PJ; Lin JH
Pharm Res; 1994 Mar; 11(3):438-41. PubMed ID: 8008713
[TBL] [Abstract][Full Text] [Related]
9. Binding of sulfonamides to carbonic anhydrase: influence on distribution within blood and on pharmacokinetics.
Boddy A; Edwards P; Rowland M
Pharm Res; 1989 Mar; 6(3):203-9. PubMed ID: 2498861
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of ibandronate in Caucasian and Japanese healthy males and postmenopausal females.
Pillai G; Gieschke R; Goggin T; Barrett J; Worth E; Steimer JL
Int J Clin Pharmacol Ther; 2006 Dec; 44(12):655-67. PubMed ID: 17190376
[TBL] [Abstract][Full Text] [Related]
11. CYP2C9 and CYP2C19 polymorphic forms are related to increased indisulam exposure and higher risk of severe hematologic toxicity.
Zandvliet AS; Huitema AD; Copalu W; Yamada Y; Tamura T; Beijnen JH; Schellens JH
Clin Cancer Res; 2007 May; 13(10):2970-6. PubMed ID: 17504998
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics meta-analysis of plitidepsin (Aplidin) in cancer subjects.
Nalda-Molina R; Valenzuela B; Ramon-Lopez A; Miguel-Lillo B; Soto-Matos A; Perez-Ruixo JJ
Cancer Chemother Pharmacol; 2009 Jun; 64(1):97-108. PubMed ID: 18941750
[TBL] [Abstract][Full Text] [Related]
13. A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours.
Siegel-Lakhai WS; Zandvliet AS; Huitema AD; Tibben MM; Milano G; Girre V; Diéras V; King A; Richmond E; Wanders J; Beijnen JH; Schellens JH
Br J Cancer; 2008 Apr; 98(8):1320-6. PubMed ID: 18414469
[TBL] [Abstract][Full Text] [Related]
14. A population approach to eplerenone pharmacokinetics and saturable protein binding.
Mori Y; Chiba K; Takahashi H; Ogata H
Drug Metab Pharmacokinet; 2010; 25(6):551-9. PubMed ID: 20962434
[TBL] [Abstract][Full Text] [Related]
15. Dose-dependent pharmacokinetics of MK-417, a potent carbonic anhydrase inhibitor, in experimental polycythemic and anemic rats.
Lin JH; Chen IW; deLuna FA
Pharm Res; 1991 May; 8(5):608-14. PubMed ID: 1866376
[TBL] [Abstract][Full Text] [Related]
16. Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies.
Soto E; Keizer RJ; Trocóniz IF; Huitema AD; Beijnen JH; Schellens JH; Wanders J; Cendrós JM; Obach R; Peraire C; Friberg LE; Karlsson MO
Invest New Drugs; 2011 Oct; 29(5):984-95. PubMed ID: 20449627
[TBL] [Abstract][Full Text] [Related]
17. Simulation of the pharmacokinetic profile of methazolamide in blood: effect of erythrocyte carbonic anhydrase binding on drug disposition.
AbuTarif MA; Taft DR
Pharm Res; 2002 Apr; 19(4):551-5. PubMed ID: 12033394
[No Abstract] [Full Text] [Related]
18. A population pharmacokinetic model of intravenous telavancin in healthy individuals to assess tissue exposure.
Ullah S; Matzneller P; Zeitlinger M; Fuhr U; Taubert M
Naunyn Schmiedebergs Arch Pharmacol; 2019 Sep; 392(9):1097-1106. PubMed ID: 31062064
[TBL] [Abstract][Full Text] [Related]
19. Teicoplanin physiologically based pharmacokinetic modeling offers a quantitative assessment of a theoretical influence of serum albumin and renal function on its disposition.
Emoto C; Johnson TN; Yamada T; Yamazaki H; Fukuda T
Eur J Clin Pharmacol; 2021 Aug; 77(8):1157-1168. PubMed ID: 33527208
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic modelling of the plasma protein binding of mycophenolic acid in renal transplant recipients.
van Hest RM; van Gelder T; Vulto AG; Shaw LM; Mathot RA
Clin Pharmacokinet; 2009; 48(7):463-76. PubMed ID: 19691368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
